PROSTIN F2 ALPHA SOLUTION

Country: Kanada

Bahasa: Inggeris

Sumber: Health Canada

Bahan aktif:

DINOPROST (DINOPROST TROMETHAMINE)

Boleh didapati daripada:

PFIZER CANADA ULC

Kod ATC:

G02AD01

INN (Nama Antarabangsa):

DINOPROST

Dos:

5MG

Borang farmaseutikal:

SOLUTION

Komposisi:

DINOPROST (DINOPROST TROMETHAMINE) 5MG

Laluan pentadbiran:

INTRA-AMNIOTIC

Unit dalam pakej:

1ML

Jenis preskripsi:

Prescription

Kawasan terapeutik:

OXYTOCICS

Ringkasan produk:

Active ingredient group (AIG) number: 0131402001; AHFS:

Status kebenaran:

CANCELLED POST MARKET

Tarikh kebenaran:

2018-09-30

Ciri produk

PRODUCT MONOGRAPH
PR
PROSTIN
® F
2α
(Dinoprost Tromethamine, USP)
Sterile solution for injection
5 mg/mL
PROSTAGLANDIN
Pfizer Canada Inc.
Date of Preparation:
17,300 Trans-Canada Highway
25 September 2003
Kirkland, Quebec H9J 2M5
Date of Revision:
06 November 2014
Control No.175411
®
TM Pfizer Enterprises, SARL
Pfizer Canada Inc., Licensee
©
Pfizer Canada Inc. 2014
_Prostin_
_ F_
2α
_ (dinoprost tromethamine)_
_ Product Monograph _
_Page 2 of 19_
_ _
_`_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS AND PRECAUTIONS
..........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
5
DRUG INTERACTIONS
............................................................................................................
8
DOSAGE AND ADMINISTRATION
........................................................................................
8
OVERDOSAGE
..........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
10
STORAGE AND STABILITY
..................................................................................................
10
SPECIAL HANDLING
INSTRUCTIONS................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 10
PART II: SCIENTIFIC INFORMATION
.........